Literature DB >> 22232308

The risk of immune thrombocytopenic purpura after vaccination in children and adolescents.

Sean T O'Leary1, Jason M Glanz, David L McClure, Aysha Akhtar, Matthew F Daley, Cynthia Nakasato, Roger Baxter, Robert L Davis, Hector S Izurieta, Tracy A Lieu, Robert Ball.   

Abstract

BACKGROUND: The risk of immune thrombocytopenic purpura (ITP) after childhood vaccines other than measles-mumps-rubella vaccine (MMR) is unknown.
METHODS: Using data from 5 managed care organizations for 2000 to 2009, we identified a cohort of 1.8 million children ages 6 weeks to 17 years. Potential ITP cases were identified by using diagnostic codes and platelet counts. All cases were verified by chart review. Incidence rate ratios were calculated comparing the risk of ITP in risk (1 to 42 days after vaccination) and control periods.
RESULTS: There were 197 chart-confirmed ITP cases out of 1.8 million children in the cohort. There was no elevated risk of ITP after any vaccine in early childhood other than MMR in the 12- to 19-month age group. There was a significantly elevated risk of ITP after hepatitis A vaccine at 7 to 17 years of age, and for varicella vaccine and tetanus-diphtheria-acellular pertussis vaccine at 11 to 17 years of age. For hepatitis A, varicella, and tetanus-diphtheria-acellular pertussis vaccines, elevated risks were based on one to two vaccine-exposed cases. Most cases were acute and mild with no long-term sequelae.
CONCLUSIONS: ITP is unlikely after early childhood vaccines other than MMR. Because of the small number of exposed cases and potential confounding, the possible association of ITP with hepatitis A, varicella, and tetanus-diphtheria-acellular pertussis vaccines in older children requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22232308     DOI: 10.1542/peds.2011-1111

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  25 in total

Review 1.  Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases.

Authors:  Carlo Perricone; Fulvia Ceccarelli; Gideon Nesher; Elisabetta Borella; Qasim Odeh; Fabrizio Conti; Yehuda Shoenfeld; Guido Valesini
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  Vaccine administration and the development of immune thrombocytopenic purpura in children.

Authors:  Valerio Cecinati; Nicola Principi; Letizia Brescia; Paola Giordano; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

3.  Physicians' confidence in vaccine safety studies.

Authors:  Sean T O'Leary; Mandy A Allison; Shannon Stokley; Lori A Crane; Laura P Hurley; Brenda Beaty; Allison Kempe
Journal:  Prev Med       Date:  2013-01-15       Impact factor: 4.018

4.  Public health: An injection of trust.

Authors:  Michael Eisenstein
Journal:  Nature       Date:  2014-03-06       Impact factor: 49.962

5.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

Review 6.  Clinical practice: immune thrombocytopenia in paediatrics.

Authors:  Veerle Labarque; Chris Van Geet
Journal:  Eur J Pediatr       Date:  2014-01-05       Impact factor: 3.183

7.  Bias and estimation under misspecification of the risk period in self-controlled case series studies.

Authors:  Luis Fernando Campos; Damla Şentürk; Yanjun Chen; Danh V Nguyen
Journal:  Stat (Int Stat Inst)       Date:  2017-10-20

8.  Newly diagnosed immune thrombocytopenia: update on diagnosis and management.

Authors:  Deepak Bansal; Aruna Rajendran; Sunit Singhi
Journal:  Indian J Pediatr       Date:  2013-10-05       Impact factor: 1.967

Review 9.  Innate and adaptive immunity in immune thrombocytopenia.

Authors:  Alan H Lazarus; John W Semple; Douglas B Cines
Journal:  Semin Hematol       Date:  2013-01       Impact factor: 3.851

Review 10.  Safety of human papillomavirus vaccines: a review.

Authors:  Kristine K Macartney; Clayton Chiu; Melina Georgousakis; Julia M L Brotherton
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.